CELLULAR TARGETED PHARMACEUTICALLY ACTIVE SUBSTANCE OR LABEL DELIVERY SYSTEM

Abstract

The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and an active pharmaceutically active substance and/or label as well as methods for producing such isolated cellular targeted delivery system and uses of such system for prophylaxis, therapy, diagnosis or theragnosis, in particular for prophylactic or therapeutic vaccination, therapy of cancer, particularly metastatic cancer or inflammatory diseases.

Claims

1. An isolated targeted delivery system comprising a CD45.sup.+ monocyte, CD45.sup.+ monocyte-macrophage, CD45.sup.+ lymphocyte and/or CD45.sup.+ granulocyte comprising within said cell a complex of one or more iron binding proteins and a pharmaceutically active substance, label or pharmaceutically active substance and label.

2. An isolated targeted delivery system comprising a CD45.sup.+ leukocyte cell comprising one or more label, in particular radiolabels or their conjugates and combinations.

3. The isolated targeted delivery system according to claim 1, wherein the CD45.sup.+ leukocyte cell is producible from a CD34.sup.+ hematopoietic precursor cell.

4. The isolated targeted delivery system according to claim 3, wherein (i) the monocyte is a CD11b.sup.+ monocyte, but is not a dendritic cell which differentiation is controlled by following transcription factors: IFN-regulatory factor 8 (IRF8), nuclear factor interleukin (IL)-3-regulated protein (NFIL3), basic leucine zipper transcriptional factor ATF-like 3 (BATF3) or transcription factor RelB (RELB), Spi-1 Proto-Oncogene (PU/1), recombining binding protein suppressor of hairless (RBPJ), IFN-regulatory factor 4 (IRF4) or transcription factor E2-2 (also known as TCF4); (ii) the differentiated monocyte is selected from the group consisting of a macrophage, an activated macrophage, a monocyte-macrophage or an activated monocyte-macrophage expressing at least one chemokine receptor, or at least one growth factor receptor; (iii) the lymphocyte is selected from the group consisting of a CD3.sup.+ and CD4.sup.+ or CD8.sup.+ T lymphocyte, or a CD19.sup.+, CD20.sup.+, CD21.sup.+, CD19.sup.+ CD20.sup.+, CD19.sup.+ CD21.sup.+, CD20.sup.+ CD21.sup.+, or CD19.sup.+ CD20.sup.+ CD21.sup.+ B lymphocyte, and a natural killer (NK) cell; or (iv) the granulocyte is selected from the group consisting of a neutrophil, an eosinophil and a basophil.

5. The isolated targeted delivery system of claim 4, wherein the activated macrophage: (i) is producible by in vitro incubation of a monocyte or macrophage with a factor capable of altering expression markers on macrophages; or with a factor capable of altering the macrophages ability to secrete cytokines; (ii) is characterized by expression of at least one of following antigens: CD64, CD86, CD16, CD32, high expression of MHCII, and/or production of iNOS and/or IL-12; (iii) is producible by in vitro incubation of a monocyte or macrophage with a factor capable of inducing the ability of the macrophage to phagocytose; (iv) is characterized by expression of at least one of following antigens: CD204, CD206, CD200R; CCR2, transferrin receptor (TfR), CXC-motive chemokine receptor 4 (CXCR4), CD163, and/or T cell immunoglobulin-domain and mucin-domain 2 (TIM-2), and/or show low expression of MHCII; (v) has the ability to phagocytose; and/or (vi) is capable of cytokine secretion, or production of inducible nitric oxide synthetase (iNOS) or other pro-inflammatory compounds, arginase or other immunosuppressive/anti-inflammatory compounds.

6. The targeted delivery system according to claim 5, wherein the factor capable of altering expression markers on macrophages is an M1 inducer or an M2 inducer, wherein: (i) the M1 inducer is selected from the group consisting of LPS, INF-γ, and viral and bacterial infection; or (ii) the M2 inducer is selected from the group consisting of IL-4, IL-10, IL-13, immune complex of an antigen and antibody, IgG, heat activated gamma-globulin, glucocorticosteroid, TGF-β, IL-1R, CCL-2, IL-6, M-CSF, PPARγ agonist, Leukocyte inhibitory factor, adenosine, helminth and fungal infection.

7. The isolated targeted delivery system of claim 4, wherein the monocyte-macrophage cell: (i) is producible from a CD34.sup.+ hematopoietic precursor cell; (ii) is producible by in vitro incubation of monocytes/monocyte-macrophage with at least one inducer; (iii) is characterized by expression of at least one of the following antigens: TfR.sup.+, CD163.sup.+, TIM-2.sup.+, CD14.sup.+, CD16.sup.+, CD33.sup.+, and/or CD115.sup.+; (iv) is characterized by expression of at least one of the following antigens: TfR.sup.+, CD163.sup.+, TIM-2.sup.+, CXCR4.sup.+, CD14.sup.+, and/or CD16.sup.+; and/or (v) has the ability to phagocytose.

8. The targeted delivery system according to claim 7, wherein the inducer is an M1 inducer or an M2 inducer, wherein: (i) the M1 inducer is selected from the group consisting of LPS, INF-γ, or viral or bacterial infection; (ii) the M2 inducer is selected from the group consisting of IL-4, IL-10, IL-13, immune complex of an antigen and antibody, IgG, heat activated gamma-globulins, glucocorticosteroids, TGF-β, IL-1R, CCL-2, IL-6, M-CSF, PPARγ agonist, leukocyte inhibitory factor, cancer-conditioned medium, cancer cells, adenosine and helminth or fungal infection.

9. The isolated targeted delivery system of claim 4, wherein the lymphocyte: (i) is obtainable from blood, spleen, or bone marrow or is producible from a CD34.sup.+ precursor cell; (ii) is an immunologically competent lymphocyte; (iii) expresses antigen specific T cell receptors; and/or (iv) is characterized by expression of at least one of the following antigens: (a) CD3.sup.+ and CD4.sup.+ or CD8.sup.+ or (b): CD19.sup.+, CD20.sup.+, CD21.sup.+, CD19.sup.+ CD20.sup.+, CD19.sup.+ CD21.sup.+, CD20.sup.+ CD21.sup.+, or CD19.sup.+ CD20.sup.+ CD21.sup.+ antigen.

10. The isolated targeted delivery system of claim 4, wherein the granulocyte: (i) is obtainable from blood, spleen or bone marrow or producible from a CD34.sup.+ precursor cell; (ii) is characterized by expression of at least one of the following CD66b.sup.+ and/or CD193.sup.+; (iii) is a polymorphonuclear leukocyte characterized by the presence of granules in their cytoplasm; and/or (iv) is characterized by expression of at least one of the following: TfR.sup.+, CD163.sup.+, TIM-2.sup.+, and/or CXCR4.sup.+.

11. The isolated targeted delivery system of claim 4, wherein the NK cell: (i) is obtainable from blood, spleen or bone marrow or producible from a CD34.sup.+ precursor cell; and/or (ii) is characterized by the lack of CD3 expression and expression of at least one of the following CD56.sup.+ and/or CD94.sup.+, CD158a.sup.+ CD158f.sup.+ CD314.sup.+ CD335.sup.+.

12. The isolated targeted delivery system of claim 1, wherein the iron binding protein is selected from the group consisting of ferritin haemoglobin, haemoglobin-haptoglobin complex, hemopexin, transferrin; and lactoferrin.

13. The isolated targeted delivery system according to claim 1, wherein the pharmaceutically active substance is selected from the group consisting of a protein, a nucleic acid, a non-protein non-nucleic acid compound with a molecular weight of less than 1.5 kD; an anticancer drug; an anti arteriosclerotic drug; and anti-inflammatory drug; and photosensitizing compound; a virus; and a α or β radiation emitting radioisotope, which also emit a cell damaging amount of γ radiation, or a complex of the compound or isotope linked to a nanoparticle.

14. The isolated targeted delivery system according to claim 13, wherein the anticancer drug is selected from the group consisting of an apoptosis-inducing drug, an alkylating substance, anti-metabolites, antibiotics, epothilones, nuclear receptor agonists and antagonists, an anti-androgene, an anti-estrogen, a platinum compound, a hormone, an antihormone, an interferon, an inhibitor of cell cycle-dependent protein kinases (CDKs), an inhibitor of cyclooxygenases and/or lipoxygenases, a biogeneic fatty acid, a biogenic fatty acid derivative, prostanoids, leukotrienes, an inhibitor of protein kinases, an inhibitor of protein phosphatases, an inhibitor of lipid kinases, a platinum coordination complex, an ethyleneimine, a methylmelamine, a triazine, a vinca alkaloid, a pyrimidine analog, a purine analog, an alkylsulfonate, a folic acid analog, an anthracendione, a substituted urea, a methylhydrazin derivative, an ene-diyne antibiotic, a maytansinoid an auristatine derivate, immune check-point inhibitor, and an inhibitor of tumour-specific protein or marker.

15. The isolated targeted delivery system according to claim 13, wherein the anticancer drug is a acediasulfone, aclarubicine, ambazone, aminoglutethimide, L-asparaginase, azathioprine, banoxantrone, bendamustine, bleomycin, busulfan, calcium folinate, carboplatin, carpecitabine, carmustine, celecoxib, chlorambucil, cis-platin, cladribine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin dapsone, daunorubicin, dibrompropamidine, diethylstilbestrole, docetaxel, doxorubicin, enediynes, epirubicin, epothilone B, epothilone D, estramucin phosphate, estrogen, ethinylestradiole, etoposide, flavopiridol, floxuridine, fludarabine, fluorouracil, fluoxymesterone, flutamide fosfestrol, furazolidone, gemcitabine, gonadotropin releasing hormone analog, hexamethylmelamine, hydroxycarbamide, hydroxymethylnitrofurantoin, hydroxyprogesteronecaproat, hydroxyurea, idarubicin, idoxuridine, ifosfamide, interferon α, irinotecan, leuprolide, lomustine, lurtotecan, mafenide sulfate olamide, mechlorethamine, medroxyprogesterone acetate, megastrolacetate, melphalan, mepacrine, mercaptopurine, methotrexate, metronidazole, mitomycin C, mitopodozide, mitotane, mitoxantrone, mithramycin, nalidixic acid, nifuratel, nifuroxazide, nifuralazine, nifurtimox, nimustine, ninorazole, nitrofurantoin, nitrogen mustards, oleomucin, oxolinic acid, pentamidine, pentostatin, phenazopyridine, phthalylsulfathiazole, pipobroman, prednimustine, prednisone, preussin, procarbazine, pyrimethamine, raltitrexed, rapamycin, rofecoxib, rosiglitazone, salazosulfapyridine, scriflavinium chloride, semustine streptozocine, sulfacarbamide, sulfacetamide, sulfachlopyridazine, sulfadiazine, sulfadicramide, sulfadimethoxine, sulfaethidole, sulfafurazole, sulfaguanidine, sulfaguanole, sulfamethizole, sulfamethoxazole, co-trimoxazole, sulfamethoxydiazine, sulfamethoxypyridazine, sulfamoxole, sulfanilamide, sulfaperin, sulfaphenazole, sulfathiazole, sulfisomidine, staurosporin, tamoxifen, taxol, teniposide, tertiposide, testolactone, testosteronpropionate, thioguanine, thiotepa, tinidazole, topotecan, triaziquone, treosulfan, trimethoprim, trofosfamide, UCN-01, vinblastine, vincristine, vindesine, vinblastine, vinorelbine, and zorubicin.

16. The isolated targeted delivery system according to claim 13 wherein the immunomodulatory drugs activate or inhibit activity of immune cells.

17. The isolated targeted delivery system according to claim 13, wherein the anticancer drug is a proliferation inhibiting protein, or an antibody or antibody like binding protein that specifically binds to a proliferation promoting protein or a nucleic acid.

18. The isolated targeted delivery system according to claim 1, wherein the pharmaceutically active substance is a hypoxia-activated prodrug.

19. The isolated targeted delivery system according to claim 1, wherein the pharmaceutically active substance is an antigen or a nucleic acid encoding an antigen.

20. The isolated targeted delivery system of claim 1, wherein the label is selected from the group consisting of a fluorescent dye, a fluorescence emitting isotope, a radioisotope, a detectable polypeptide, a nucleic acid encoding a detectable polypeptide and a contrast agent.

21. The isolated targeted delivery system of claim 1, wherein the label comprises a chelating agent which forms a complex with divalent or trivalent metal cations.

22. The isolated targeted delivery system of claim 21, wherein the chelating agent is selected from the group consisting of 1,4,7,10-tetraazacyclododecane-N,N′,N,N′-tetraacetic acid (DOTA), ethylenediaminetetraacetic acid (EDTA), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), triethylenetetramine (TETA), iminodiacetic acid, Diethylenetriamine-N,N,N′,N′,N″-pentaacetic acid (DTPA) and 6-Hydrazinopyridine-3-carboxylic acid (HYNIC).

23. The isolated targeted delivery system of claim 14, wherein the contrast agent comprises a paramagnetic agent.

24. The isolated targeted delivery system of claim 20, wherein the radioisotope/fluorescence emitting isotope is selected from the group consisting of alpha radiation emitting isotopes, gamma radiation emitting isotopes, Auger electron emitting isotopes, X-ray emitting isotopes, fluorescent isotopes, such as .sup.65Tb, fluorescence emitting isotopes, such as .sup.18F, .sup.51Cr, .sup.67Ga, .sup.68Ga, .sup.89Zr, .sup.111In, .sup.99mTc, .sup.140La, .sup.175Yb, .sup.153Sm, .sup.166Ho, .sup.88Y, .sup.90Y, .sup.149Pm, .sup.177Lu, .sup.47Sc, .sup.142Pr, .sup.159Gd, .sup.212Bi, .sup.72As, .sup.72Se, .sup.97Ru, .sup.109Pd, .sup.105Rh, .sup.101m15Rh, .sup.119Sb, .sup.128Ba, .sup.123I, .sup.124I, .sup.131I, .sup.197Hg, .sup.211At, .sup.169Eu, .sup.203Pb, .sup.212Pb, .sup.64Cu, .sup.67Cu, .sup.188Re, .sup.186Re, .sup.198Au and .sup.199Ag as well as conjugates and combinations of above with proteins, peptides, small molecular inhibitors, antibodies or other compounds.

25. The isolated targeted delivery system of claim 20, wherein the fluorescence dye is selected from the group consisting of the following classes of fluorescent dyes: xanthens, acridines, oxazines, cynines, styryl dyes, coumarines, porphines, metal-ligand-complexes, fluorescent proteins, nanocrystals, perylenes and phtalocyanines as well as conjugates and combinations of these classes of dyes.

26. The isolated targeted delivery system according to claim 20, wherein the detectable polypeptide is an autofluorescent protein.

27. The isolated targeted delivery system according to claim 1, wherein: (i) the bond(s) between the iron binding protein(s) and the pharmaceutically active substance, label or pharmaceutically active substance and label comprised in the complex are covalent and/or non-covalent; and/or (ii) the pharmaceutically active substance, label or pharmaceutically active substance and label comprised in the complex is entrapped/encapsulated by the iron binding protein or multimers thereof.

28. Method of preparation of the isolated targeted delivery system of claim 1 comprising steps of a) providing purified iron binding protein; b) covalently or non-covalently linking a pharmaceutically active substance, label or pharmaceutically active substance and label to and/or encapsulating a pharmaceutically active substance, label or pharmaceutically active substance and label in an iron binding protein; c) providing a CD45.sup.+ leukocyte cell; and d1) incubating the CD45.sup.+ leukocyte cell in the presence of the iron binding protein produced in step b) until the CD45.sup.+ leukocyte cell is at least partially loaded with the complex of the iron binding protein and the a pharmaceutically active substance, label or pharmaceutically active substance and label produced in step b); and/or d2) incubating CD45.sup.+ leukocyte cell in the presence of the label until the CD45.sup.+ leukocyte cell is at least partially labelled with the label.

29. The isolated targeted delivery system of claim 1 or producible according to the method of claim 28 for use as a medicament or diagnostic.

30. A pharmaceutical composition comprising the isolated targeted delivery system of claim 1 and a pharmaceutically acceptable carrier and/or suitable excipient(s).

31. A method for preventing, treating or diagnosing a tumour, an inflammatory disease or ischemic areas, or for prophylactic of therapeutic vaccination, comprising administration of the isolated targeted delivery system of claim 1 in an effective amount to a patient in need thereof.

Description

BRIEF DESCRIPTION OF DRAWINGS

[0182] FIG. 1: Panel (A) shows a minimal active fragment of a consensus amino acid sequence among mammalian ferritin H chains and two full length consensus sequences based on several mammalian ferritin H chains (see SEQ ID NO: 1, 2 and 7, respectively) as well as a minimal and full length amino acid sequence of mouse (SEQ ID NO: 3 and 4) and human (SEQ ID NO: 5 and 6) ferritin H chain. Panel (B) shows a a minimal active fragment of a consensus amino acid sequence among mammalian ferritin L chains and two full length consensus sequences based on several mammalian ferritin L chains (see SEQ ID NO: 8, 9 and 14, respectively) as well as a minimal and full length amino acid sequence of mouse (SEQ ID NO: 10 and 11) and human (SEQ ID NO: 12 and 13) ferritin L chain. Panel (C) shows a minimal active fragment of a consensus amino acid sequence among mammalian haemoglobin alpha chains and one full length consensus sequences based on several mammalian haemoglobin alpha chain (see SEQ ID NO: 15 and 16, respectively) as well as a minimal and full length amino acid sequence of human (SEQ ID NO: 17 and 18) haemoglobin alpha chain. Panel (D) shows a minimal active fragment of a consensus amino acid sequence among mammalian haemoglobin beta chains and a full length consensus sequences based on several mammalian haemoglobin beta chain (see SEQ ID NO: 19 and 20, respectively) as well as a minimal and full length amino acid sequence of human (SEQ ID NO: 21 and 22) haemoglobin beta chain. Panel (E) shows a N- and C-terminal minimal active fragment of a consensus amino acid sequence among mammalian transferrins (SEQ ID NO: 23 and 24) and a full length consensus sequences based on several mammalian transferrins (SEQ TD NO: 25) as well as a N- and C-terminal minimal active fragment of a human transferrin (SEQ ID NO: 26 and 27) and full length amino acid sequence of human transferrin (SEQ ID NO: 28). In the consensus sequences X indicates a position that is variable and stands for any natural amino acid. Preferably, in each case X in dependently of other X stands for the amino acid present in the human protein.

[0183] FIG. 2: Shows macrophage inside the mouse tumour mass (TRITC stained before injection, loaded with FITC-decorated ferritin).

[0184] FIG. 3: Shows confocal microscopy image of tumour tissue mouse injected with mammary cancer cells and given i.v. macrophages loaded with FITC-ferritin (asterix)—it is clearly observed, not only in macrophages but also in cancer cells, that ferritin-FITC spread within all tumour mass.

[0185] FIG. 4: Shows snapshots of one channel (in original green channel converted to the grey-scale picture) recording using confocal microscopy of macrophages (indicated with *; loaded with FITC-ferritin) and cancer cell (indicated with arrow; stained with red label and therefore not observed in green channel before ferritin uptake) in vitro taken at the starting time point (A) and after time long enough to fill cancer cell with ferritin (B). FITC-ferritin was dynamically transported to the cancer cell (accumulating firstly in the vesicles; then spreading to the whole cytoplasm as seen at this image (the cell appeared in green channel).

[0186] FIG. 5: Shows survival of mice receiving placebo and macrophages loaded with ferritin-coupled melphalan and ferritin-coupled chlorambucil.

[0187] FIG. 6: Shows tumour cells apoptosis caused by treatment with cyclophosphamide and cyclophosphamide encapsulated in ferritins loaded to macrophages (given at the same doses).

[0188] FIG. 7: Shows MRI images of mouse mammary tumour. The mouse was treated (at time point 0 h) with macrophages (i.v. injection) loaded with ferritin Fh. Then we observed increased diameter of blood vessels (arrow) filled with injected macrophages (giving significant T2-signal reduction) and afterword macrophages spread to the tissue (spot-like pattern; arrows). These changes (in the same time points) were observed in all examined mice.

[0189] FIG. 8: Shows ferritin, haemoglobin and transferrin uptake by macrophages, ferritin and haemoglobin uptake by monocytes and ferritin uptake by lymphocytes and granulocytes.

[0190] FIG. 9: Shows the stability of the ferritin storage by macrophages.

[0191] FIG. 10: Shows transfer of ferritin, haemoglobin and transferrin from macrophage to various cancer cells.

[0192] FIG. 11: Shows the transfer of ferritin from macrophage to cancer and non-cancer cells.

[0193] FIG. 12: Shows the transfer of ferritin encapsulated with hypoxia activated prodrug from macrophage to cancer cells.

[0194] FIG. 13: Shows the apoptosis in cancer cells that received ferritin with encapsulated various anticancer agents from co-cultured macrophages or soluble ferritin with the same agents.

[0195] FIG. 14: Shows the transfer of ferritin, haemoglobin and transferrin from monocyte to various cancer cells.

[0196] FIG. 15: Shows the transfer of ferritin and haemoglobin from granulocyte to various cancer cells.

[0197] FIG. 16: Shows the transfer of ferritin and haemoglobin from lymphocyte to various cancer cells.

[0198] FIG. 17: Shows the picture from two-photon microscopy showing tumour from a mouse that received pre-labeled (before administration) macrophages containing Ferritin-FITC.

[0199] FIG. 18: Shows the whole body imaging of mice that intravenously received labeled macrophages, showing their accumulation in the tumour site and their distribution in other organs.

[0200] FIG. 19: Shows the migration of macrophages to hypoxic tissue, a cross-section of the tumour from a mouse that was administered intravenously with pre-labeled macrophages, tumour hypoxic areas are visualized with a hypoxia marker—pimonidazolone.

[0201] FIG. 20: Shows the presents localization of vesicles containing FITC-laded ferritin (round objects) in the microenvironment inside the tumour mass. Macrophages containing FITC-laded ferritin were administered intravenously to the mouse.

[0202] FIG. 21: Shows the signal recorded by PET from a whole-body analysis of mice with the metastatic 4T1 cancer. Mice received intravenously macrophages loaded with .sup.18F-FDG. Signal accumulation is increased in the lungs of mice with micrometastases (confirmed by pathology examination). Mice receiving plain .sup.18F-FDG, or mice without 4T1 cancer had lower PET signal. MQ-FDG: indicates mice with metastatic 4T1 tumour+intravenous macrophages loaded with .sup.18F-FDG. FDG: indicates mice with metastatic 4T1 tumour+intravenous free .sup.18F-FDG. Naive mice MQ-FDG: Indicates naive mice without tumour+intravenous macrophages loaded with .sup.18F-FDG.

[0203] FIG. 22: Shows the tumour homing by different CD45+ leukocyte cell types usable in the targeted delivers systems of the invention. Mice with CT26 tumors (marked by the arrows) were intravenously injected with PBS or fluorescently labelled cells. Panel A.—PBS, no cells added, Panel B.—shows homing of a CD45.sup.+ leukocyte subpopulation, Panel C. shows homing of activated CD4.sup.+ T lymphocytes, Panel D. shows homing of a macrophage-monocytic cell line. 24 hours after injection mice were anaesthetized and imaged. Panel E. Shows the quantification of the tumour homing by different CD45+ leukocyte cells.

[0204] FIG. 23: Shows Survival of mice with CT26 tumor receiving therapy with monocytes loaded with ferritin-Cisplatin. n=6-8 mice/group. Survival of the mice was calculated by reaching (1500 mm3) maximum-allowed tumour volume (measured by caliper, according to formula A×B2).

[0205] FIG. 24: Shows targeting of intravenously administered cells to inflamed (arthritic) joints Control mouse (panel A.) or a mouse with severe inflammation of the joints (panel B.) have been intravenously injected with macrophage-monocyte cell line. Before injection cells were labelled with fluorescent tracer. 24 hours after injection joints were removed and single cell suspension generated. Cells have been analyzed by flow cytometry. Fluorescently labelled cells are presented in the P2 area. Panel C. shows quantification of the fluorescent cells in the inflamed than in control joints. Macrophage-monocyte cells are present with greater number in the inflamed than in control joints.

[0206] FIG. 25: Shows targeting of intravenously administered cells to the lymph nodes. Control mouse (panel A.) or a mouse with severe inflammation of the joints (panel B.) have been intravenously injected with activated macrophages (with M-CSF and CCL2). Before injection cells were labelled with fluorescent tracer. 24 hours after injection mice were anaesthetized and imaged. Mice with inflammatory condition have positive signal derived from cell-tracer, from the lymph nodes (marked by white arrows).

[0207] FIG. 26: Shows radiolabeling of monocyte-macrophage cell line with plain .sup.89Zr-oxinate, i.e. without iron binding protein (˜1.85 MBq) for PET imaging. Radioactivity of cells after loading with .sup.89Zr is indicated in MBq.

[0208] FIG. 27: Ferritin transfer was examined in cancer cells (EMT6) co-cultured with ferritin-loaded macrophages (RAW264.7) for 2 hrs. Three experimental conditions were used: “ctrl” (normal co-culture, no stress); “EMT6 OS” when EMT6 cells were subjected to the oxidative stress before co-culture and then co-cultured with macrophages at normoxic conditions and “co-culture OS” when both cell types were subjected to the oxidative stress before the co-culture. Results showed that cancer cells subjected to the oxidative stress received (from macrophages) more ferritins than control cells. The uptake was even more efficient when both cell types were subjected to the oxidative stress. It can be related with higher load of ferritin due to oxidative stress and therefore more efficient transfer, or oxidative stress triggers macrophages to more efficiently deliver ferritins to cancer cells in order to reduce oxidative stress in neighboring cells. Panel A shows: Ferritin uptake from macrophages (2 hrs co-culture) in oxidative stress (oxidative glucose treatment for 16 hrs). Panel B shows: Ferritin uptake from macrophages (2 hrs co-culture) in oxidative stress (oxidative glucose treatment for 16 hrs).

EXAMPLE SECTION

Example 1—Activation of Macrophages

[0209] Macrophages for use according to the present invention were obtained, differentiated and activated as follows. In order to activate macrophages, they are obtained firstly from bone marrow precursors (for example see paper: Weischenfeld and Porse, 2008, CSH Protoc, doi. 10.1101/pdb.prot.5080) or blood monocytes. Alternatively, they can be obtained from peritoneum. The methods of macrophage isolation, culture, differentiation and polarization/activation are well known for those skilled in the art. For example, they have been described in details by Murray et al. (Immunity, 2014, 41(1):14-20).

[0210] In this practical realization of the invention bone marrow derived macrophages were obtained from BALB/c or C57Bl/6 mouse, however canine blood-monocyte-derived macrophages or commercially available macrophage cell lines (monocyte-macrophage lineage mouse cells: RAW 264.7, J744, human: THP-1, U937, or canine DH82 cell line).

[0211] Shortly, such bone marrow derived macrophages are seeded in plastic Petri dish in 5 ml medium (3 ml cells per plate): DMEM:F12+glutamine/glutamax+10% FBS+Penicillin/Streptomycin and 20% of L929 conditioned medium or M-CSF (50 ng/ml). In the next five days the medium is supplemented in growth factor and one of the activating compounds or their combinations as one cytokine cocktail.

[0212] Alternatively, macrophages have been cultured in “M1/M2 Macrophage Generation Medium” (Promocell) or equivalent commercially available or self-made medium containing all the necessary cytokines and interleukins to consider them as activated.

[0213] In order to obtain macrophages from blood monocytes, fresh blood (not older than 12 hours) cells were purified by centrifugation using Histopaque system 1.077 g/ml or equivalent and white blood cells (or alternatively, only white blood cells collected from the blood bank) in an appropriate amount of pre-warmed Monocyte Attachment Medium (or equivalent, e.g. DMEM/RPMI supplemented with M-CSF), e.g. 15 ml Medium per T-75 flask. A seeding density should be of 1-2 million/cm.sup.2 for mononuclear cells with a monocyte content of ≥2 5% and 1.5-3 million/cm.sup.2 for a monocyte content of <25%. Then, cells are incubated for 1-1.5 hours at 5% CO.sub.2 and 37° C. in the incubator without any further manipulation.

[0214] After cell attachment, they are washed at least twice, and then an appropriate amount of complete “M1- or M2-Macrophage Generation Medium DXF” is added to the cells (e.g. 20 ml per T-75 flask) and cells are incubated for 6 days at 37° C. and 5% CO.sub.2 without medium change. In order to activate macrophages, the whole medium is replaced with medium supplemented with activating compound.

[0215] Activating compounds used in this invention (for bone-marrow derived cells or to activate cells from monocyte-macrophage cell lines) are as follows: IL-4 (20 ng/ml), IFN-γ (at least 20 ng/ml), LPS (at least 10 ng/ml), IL-13 (at least 20 ng/ml), IL-10 (at least 20 ng/ml), dexamethason (at least 20 μg/ml), CCL2 (at least 20 ng/ml), oxLDL (at least 20 ng/ml), TNF-α (20 ng/ml), TGF-β (20 ng/ml), cortisol (150-300 ng/ml) or their combinations as one cytokine cocktail. In order to obtain non-activated macrophages, the activating compound has not been added.

[0216] Reverse of the polarization/activation of macrophages (from classically activated to alternatively activated) can be reached for example by culture of macrophages in appropriate cytokines listed above for at least 48 hours.

Example 2—Monocyte Isolation

[0217] In order to obtain monocytes in this practical realization of the invention bone marrow derived or spleen-derived monocytes were obtained from BALB/c or C57Bl/6 mouse, however canine blood monocyte or commercially available monocyte cell lines were used (monocyte-macrophage lineage mouse cells: RAW 264.7, J744, human cells: THP-1, U937, or canine cells DH82).

[0218] To obtain blood monocytes, fresh blood (not older than 12 hours) cells were purified by centrifugation using Histopaque system 1.077 g/ml or equivalent and white blood cells are seeded in an appropriate amount of pre-warmed Monocyte Attachment Medium (or equivalent, e.g. DMEM/RPMI supplemented with 20 ng/ml M-CSF), e.g. 15 ml Medium per T-75 flask. Alternatively, only white blood cells collected from the blood bank (buffy coat) may be used. After cell attachment, they are washed at least twice, and adherent cells are considered as monocytes.

[0219] In order to obtain bone-marrow derived monocytes, in this practical realization of the invention monocytes were obtained from BALB/c or C57Bl/6 mouse. Shortly, such bone marrow derived precursors were isolated using Mouse Monocyte Enrichment Kit (StemCells) according to manufacturer's instructions. In order to obtain spleen derived monocytes, in this practical realization of the invention, the spleen has been mechanically dissociated to obtain single cell suspension and passed through the 70 μm cell strainer. Cells were centrifuged and supernatant was removed. Optionally erythrocyte lysis was performed prior to monocyte isolation by EasySep™ Mouse Monocyte Enrichment Kit (StemCells) according to manufacturer's instructions.

[0220] To obtain better effects of their protein loads and migration before use they may be pre-treated with activation stimuli: IL-4 (20 ng/ml), IFN-γ (at least 20 ng/ml), LPS (at least 10 ng/ml), IL-13 (at least 20 ng/ml), IL-10 (at least 20 ng/ml), dexamethason (at least 20 g/ml), CCL-2 (at least 20 ng/ml), oxLDL (at least 20 ng/ml), TNF-α (20 ng/ml), TGF-β (20 ng/ml), cortisol (150-300 ng/ml) or their combinations as one cytokine cocktail.

Example 3—Granulocyte Isolation

[0221] To obtain granulocyte cells from blood, 9 parts of blood were diluted with 1 part of ACD buffer (containing 0.17 M d-glucose, 0.10 M citric acid, 0.11 M trisodium citrate). Blood from this step was further diluted with PBS at the 1:1 ratio and centrifuged. After removing plasma and buffy coat, remaining cells were mixed with PBS to 80% of the original volume from the first step (ACD-blood) and then diluted with cold distillated water at the ratio of 4:12. Then, 6 parts of 2.7% of NaCl solution were added and centrifuged.

[0222] After removal of supernatant cells were resuspended in RPMI-1640 medium. These cell were considered as granulocytes.

Example 4—Lymphocyte Isolation

[0223] In order to obtain spleen derived lymphocytes, in this practical realization of the invention, the spleen has been mechanically dissociated to obtain single cell suspension and passed through the 70 μm cell strainer. Cells were centrifuged and supernatant was removed. After erythrocyte lysis, lymphocytes were isolated using a negative cell isolation strategy with a help of EasySep™ CD4.sup.+ Enrichment Kit (Stemcell) according to manufacturer's instructions.

[0224] Lymphocytes were activated by the 3-5 day culture in RPMI medium supplemented with glutamine/glutamax, 10% FB S, Penicillin/Streptomycin, in the presence of beads covered with anti-CD3 and anti-CD28 (Gibco) according to manufacturer's instructions.

[0225] Activation of lymphocytes was confirmed with upregulation of CD25 and CD69 cell surface expression, that was monitored by flow cytometry.

Example 5—Leukocyte (CD45.SUP.+ Cells) Isolation

[0226] In order to obtain macrophages from blood monocytes, fresh blood (not older than 12 hours) is purified by centrifugation using Histopaque system 1.077 g/ml or equivalent and white blood cells (or alternatively, only white blood cells collected from the blood bank) are used for further steps of the procedure. Alternatively, leukocytes are obtained after erythrocyte lysis of the whole blood, as it was done in this practical realization of the invention.

Example 6—Preparation of Ferritin Complexes

[0227] In order to incorporate ferritins with the anticancer drug (e.g. classic drugs like cyclophosphamide, chlorambucil, melphalan, bendamustine, banoxantrone or hypoxia-activated prodrug like TH-302) or with the “imaging contrast agents” (e.g. ferrihydride or isotope) ferritins have to be prepared before macrophage treatment. Shortly, recombinant mouse proteins according to SEQ ID NO: 4 (FIG. 1) are obtained as follows. The expression vector pET-22b containing a synthetic gene encoding ferritin protein of SEQ ID NO: 4 was transformed into E. coli BL21 (DE3). E. coli culture was grown at 37° C. to OD600 0.6 in 1 L of Luria-Bertani broth (LB) added with ampicillin (100 mg/L). Protein expression was induced by addition of 1 mM isopropyl thio-b-D-galactoside (IPTG) and the culture was incubated overnight. Cells were harvested by centrifugation (15000 g for 15 min) and suspended in 20 mM Hepes (pH 7.5), 150 mM NaCl, 0.1 mg/mL DNase, 10 mM MgCl.sub.2 and disrupted by sonication. The lysate was centrifuged at 15000 g for 30 min and the supernatant was treated 10 min at 50° C., centrifuged to remove denatured proteins and then at 70° C. for 10 min and centrifuged again. The supernatant was added with 30% (NH).sub.4SO.sub.4 at 4° C. stirring for 1 h and centrifuged at 15000 g for 30 min. The supernatant was added with 70% (NH).sub.4SO.sub.4 at 4° C. stirring for 1 h and centrifuged at 15000 g for 30 min. The pellet was resuspended in 20 mM Hepes (pH 7.5), 150 mM NaCl and dialysed overnight at 4° C. against the same buffer. The protein was loaded on a HILOAD 26/600 SUPERDEX 200 gel-filtration column (GE-Healthcare) and then sterile filtered and stored at 4° C. (FIG. 9) Protein concentration was determined spectrophotometrically at 280 nm using a molar extinction coefficient of 21000 M.sup.−1 m.sup.−1 and by Bradford assay measuring the absorbance at 595 nm.

[0228] Said ferritins include recombinant mammalian ferritin proteins H and/or L homopolymers.

[0229] Ferritins, obtained as previously described, are purified by standard methods in order to obtain an endotoxin free, pre-clinical grade product (see, for example: Ceci et al. 2011, Extremophiles 15(3):431-439; Vanucci et al. 2012, Int J Nanomed 7:1489-1509). Shortly, the ferritin conserved sterile in a storage solution containing 20 mM Hepes pH 7.5 is diluted to a final concentration of 4 uM in 24-mer in acidic solution (final pH<3.0) or, alternatively, at highly basic pH values (pH>9.5) (see for example Pontillo et al., 2016), thus allowing the dissociation of multimer. Drugs are dissolved at very high concentrations in the appropriate solvent and then a small volume is added to the ferritin solution with a 200 molar excess. PH is then brought to neutrality by addition of appropriate amounts of NaOH/HCl solutions in order to allow multimer reconstitution. Current experimental methods indicate that three/four washings using PBS (concentration steps) in 100 kDa cut off concentrators allows rapid and complete elimination both the co-solvents as well as non-encapsulated drugs and full recovery of drug loaded ferritin nanocages. The ferritin-drug complex thus obtained was then flash freezed in liquid nitrogen and lyophilised.

[0230] Depending on the choice of co-solvent and on the intrinsic chemical properties of the drug molecule, it can be estimated that up to 150-180 drug molecules can be entrapped/adsorbed within the 24-mer ferritin cage.

[0231] Pharmaceutically active substances or labels may also be covalently coupled to ferritin amino acid side chains (lysines or cysteines) by appropriate choice of phenylhydrazone, succinimide or maleimide activated drugs. Accordingly, i) phenylhydrazone derivative may breaks and liberates the drug from the ferritin surface, ii) lysine bound derivatives may become active after full protein degradation into aminoacids or iii) cysteine bound derivative may be liberated within the cell through reductive hydrolysis of the maleimede thioether link.

Example 7—Preparation of Haemoglobin-Compound Complex

[0232] Human haemoglobin is prepared from fresh red cells as described in Rossi-Fanelli et al. (Archives of biochemistry and biophysics 77:478-492, 1958). Shortly, the heparinized blood, obtained from healthy donors, was centrifuged at 1600 rpm for 30 minutes (4° C.) to sediment the RBCs. Buffy coat was accurately removed by needle aspiration on the surface of the pellet. The plasma supernatant was discarded and the RBC pellet was washed three times by resuspending the RBCs in isotonic 0.9% saline solution and centrifuging at 1600 rpm for 30 minutes at 4° C. After the final saline wash and centrifugation step, the RBC pellet was resuspended in distilled water buffered at pH 7.2 with 5 mM potassium phosphate buffer (PB, pH=7.2) and allowed to lyse at 4° C. overnight under gentle stirring. Dialyzed RBC lysate was subsequently centrifuged at 13.000 rpm for 30 min at 4° C. and supernatant was directly loaded on an ÄKTA Explorer system equipped with an XK 26/40 column packed with Q-sepharose XL resin (GE Healthcare) at room temperature. Columns were equilibrated with buffer A (20 mM Tris-HCl, pH=8.2) at a flow rate of 12 mL/min and washed three times with the same buffer. A linear gradient elution was generated by changing from 100% buffer A to 75% buffer B (20 mM Tris-Cl, plus 0.2 M NaCl pH8.20) followed by a step gradient of 100% buffer B. Upon elution, a fraction collector was used to collect protein fractions. Protein thus obtained was analyzed by SDS page and stored frozen at −80° C.

[0233] Human Haemoglobin (SEQ ID NO: 18 or 22, see FIG. 1) can be readily covalently linked to appropriate drug conjugates, host hydrophobic drug molecules within the heme binding pocket or even transport small cytotoxic molecules linked to the heme iron. Hb can be easily modified by selective attachment of the appropriate drug conjugate to the cysteine residue in position 93 of the beta chains, the only titratable cystein on the protein surface. Maleimido functionalized drugs, such as the tubuline inhibitor MonomethylAuristatin (MMAE) or the succinimide functionalized mertansine analogue (DM1-SMCC) are most notable examples of extremely potent cytotoxics that can be readily and specifically attached to the relevant cys beta93 residue (for maleimido functionalized drugs) or to one or more lysine residues (succinimide functionalized drug), respectively. These drugs have been conveniently conjugated to human haemoglobin according to the following procedures:

[0234] The auristatin E analogue, maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl-monomethyl auristatin E (vcMMAE) was obtained from Med Chem Express (Princeton, N.J.). The Haemoglobin vcMMAE adduct was prepared as follows. Human haemoglobin solution was adjusted to a concentration of 120 μM heme with reaction buffer (50 mM phosphate buffer pH 6.8, containing 0.1 mM EDTA) and conjugated with 10-fold molar excess of vcMMAE in the presence of 20% v/v acetonitrile solution at 4° C. overnight. Maleimide groups react efficiently and specifically with free (reduced) sulfhydryls at pH 6.5-7.5 to form stable thioether bonds. The excess vcMMAE was purified and buffer-exchanged with D-PBS using PM 100 ultrafiltration concentrator. The yield of conjugation was approximately 80% of the total cysteines. Formation of vcMMAE conjugate was confirmed by LC-MS analysis and by titration of residual free thiol group with p-chloromercuribenzoate. The concentrations of Hb-vcMMAE conjugates were determined by UV-vis spectroscopy analysis.

[0235] The mertansin analogue DM1 SMCC (Alb Technology Ltd, Hederson, Nev., USA), functionalized for lysine covalent attachment, was prepared as follows. Human haemoglobin solution was adjusted to a concentration of 400 μM heme with reaction buffer (0.1 mM phosphate buffer pH 7.4, containing 0.5 mM EDTA) and conjugated with 20-fold molar excess of DM1-SMCC in the presence of 10% v/v DMSO solution at 4° C. for 16 hours. The amine-reactive succinimidyl ester couples to amines thus yielding a covalent adduct with lysine groups on the surface of the protein. The excess DM1-SMCC was eliminated and buffer-exchanged with D-PBS using PM 100 ultrafiltration concentrator. The yield of conjugation was approximately 2.4 mertansine molecules per haemoglobin tetramer. Formation of DM1-SMCC conjugate was confirmed by LC-MS analysis. The concentrations of Hb-DM1-SMCC conjugates were determined by UV-vis spectroscopy analysis.

[0236] Alternatively, the apo-protein solution must be kept on an ice bath for the duration of the reconstitution process. A 1.5-fold molar excess of CuT-CPP (Cu-TCPP 4,4′,4″,4″′-(Porphine-5,10,15,20-tetrayl)tetrakis(benzoic acid)—Cu.sup.67) in 0.1 M NaOH must be added dropwise to the apo-globin solution in 0.2 M KPi buffer at pH 7.0 vortexed quickly at room temperature and then placed back in ice bath for 30 minutes. The protein solution must then be filtered in a syringe filter before use.

Example 8—Preparation of Transferrin—Compound Complex

[0237] The serum was obtained from healthy donor and excess iron was added in the presence of citrate ions as a chelator and bicarbonate, which is facilitates for iron binding to transferrin. The reaction mixture contained 6.5 mg sodium bicarbonate and 153.16 ferric citrate in pH=8, 4° C., 1 hour per 100 mL of serum. Albumin was subsequently precipitated by Rivanol (4%) by adding the alcohol solution to the serum sample in a 3.5 V/V ratio at 4° C., and pH=9.4 for 2 h. Then, the solution was centrifuged at 3000 rpm for 20 min and finally filtered by filter on a 0.8 mm syringe filter. Excess Rivanol was subsequently removed by gel-filtration on a Sephadex G-25 column in ammonium sulfate 0.025 M. A first precipitation of by saturated ammonium sulfate 50% at pH=6.5 was subsequently carried out followed by centrifugation at 3000 rpm for 10 min (immunoglobulin removal). A second precipitation at 80% saturated ammonium sulfate was then carried out thus allowing recovery of transferrin the precipitate. Solid precipitate was then dissolved in buffer of 0.06 M Tris HCl buffer, pH=8, containing 1 M NaCl. The solution was dialyzed in the same buffer to allow full removal of ammonium sulfate. Protein solution was then concentrated with a centricon PM50 centrifugal concentrator up to 10-15 mg/ml (as estimated by Bradford method) and loaded on a Sephadex G-100 gel-filtration column (2,4×80 cm) equilibrated in 1M NaCl, flow rate of 15 ml/h. Transferrin thus obtained was estimated to be 88-90% pure by SDS page. Ion-exchange chromatography by anion exchanger DEAE Sephadex A-50 was then used as a final polishing step. The transferrin sample was loaded in the column equilibrated with 0.06 M Tris HCl at pH=8 and eluted by a linear concentration gradient with elution buffer, 0.3 M Tris HCl, pH=8. Protein purity was higher than 98% with a yield of about 150 mg per 100 mL of serum.

[0238] Human Holo-transferrin, (SEQ ID NO: 28, FIG. 1) similarly to haemoglobin can be readily covalently linked to appropriate drug conjugates, although there is only availability for lysine modifications, due to the absence of freely titratable cysteine groups. Thus the succinimide functionalized mertansine analogue (DM1-SMCC) has been used to covalently attach to one or more lysine residues (succinimide functionalized drug). The drug has been conveniently conjugated to transferrin according to the following procedure:

[0239] The mertansin analogue DM1 SMCC (Alb Technology Ltd, Hederson, Nev., USA), functionalized for lysine covalent attachment, was prepared as follows. Transferrin solution was adjusted to a concentration of 100 μM heme with reaction buffer (0.1 mM phosphate buffer pH 7.4, no EDTA in this case due to possible iron chelation effects) and conjugated with 20-fold molar excess of DM1-SMCC in the presence of 8% v/v DMSO solution at 4° C. for 16 hours. The amine-reactive succinimidyl ester couples to amines thus yielding a covalent adduct with lysine groups on the surface of the protein. The excess DM1-SMCC was eliminated and buffer-exchanged with D-PBS using PM 100 ultrafiltration concentrator. The yield of conjugation was approximately 1.5 mertansine molecule per transferring dimer. Formation of DM1-SMCC conjugate was confirmed by LC-MS analysis. The concentrations of Transferrin-DM1-SMCC conjugates were determined by UV-vis spectroscopy analysis.

[0240] Alternatively, the apo-protein solution is kept in an ice bath for the duration of the reconstitution process. A 1.5-fold molar excess of CuT-CPP (Cu-TCPP 4,4′,4″,4″′-(Porphine-5,10,15,20-tetrayl)tetrakis(benzoic acid)—Cu.sup.67) in 0.1 M NaOH must be added dropwise to the apo-globin solution in 0.2 M KPi buffer at pH 7.0 vortexed quickly at room temperature and then placed back in ice bath for 30 minutes. The protein solution must then be filtered in a syringe filter before use.

Example 9—Obtaining Ferritin Loaded Cells

[0241] Obtained cells are incubated in ferritin solution for a time and at the concentration sufficient to ensure proper ratio of ferritin/cell for their full load and also to ensure proper drug content to obtain therapeutic effect or contrast for proper imaging. The time and concentration may vary depending on the number of molecules encapsulated/adsorbed into the ferritin cage, status of cell activation, condition and number of their intended administration.

[0242] For example, to ensure proper load with ferritins, cells are incubated for 1-4 hours in ferritin solution 0.8 mg/ml in standard culture conditions. The frame of ferritin concentration may vary at least between 0.01 and 4 mg/ml as well as incubation time (5 min-6 hours or more). Adjusting time and concentration of ferritin load to cells, the influence of ferritin and treatment conditions on cell viability should be minded. Cells obtained as stated above very easily uptake ferritins in a relatively short time (in minutes; FIG. 8). Once they absorb ferritins, they do not release it to the culture medium (FIG. 9).

[0243] Nevertheless, the person skilled in the art is able to re-adjust the above conditions and optimize the protocol for the own purposes in the own laboratory.

Example 10—Obtaining Haemoglobin Loaded Cells

[0244] Obtained cells are incubated in haemoglobin solution for a time and at the concentration sufficient to ensure proper ratio of haemoglobin/cell for their full load and also to ensure proper drug content to obtain therapeutic effect or contrast for proper imaging. The time and concentration may vary depending on the number of molecules linked with the haemoglobin molecule, status of cell activation, condition and number of their intended administration.

[0245] For example, to ensure proper load with haemoglobins, cells are incubated for 1-4 hours in haemoglobin solution 0.1 mg/ml in standard culture conditions. The frame of haemoglobin concentration may vary at least between 0.01 and 0.2 mg/ml as well as incubation time (5 min-4 hours or more). Adjusting time and concentration of haemoglobin load to cells, the influence of ferritin and treatment conditions on cell viability should be minded. Cells obtained as stated above very easily uptake haemoglobins in a relatively short time (in minutes; FIG. 8).

[0246] Nevertheless, the person skilled in the art is able to re-adjust the above conditions and optimize the protocol for the own purposes in the own laboratory.

Example 11—Obtaining Transferrin Loaded Cells

[0247] Obtained cells are incubated in transferrin solution for a time and at the concentration sufficient to ensure proper ratio of transferrin/cell for their full load and also to ensure proper drug content to obtain therapeutic effect or contrast for proper imaging. The time and concentration may vary depending on the number of molecules linked with the transferrin molecule, status of cell activation, condition and number of their intended administration.

[0248] For example, to ensure proper load with transferrins, cells are incubated for 1-4 hours in transferrin solution 0.1 mg/ml in standard culture conditions. The frame of transferrin concentration may vary at least between 0.01 and 0.2 mg/ml as well as incubation time (5 min-4 hours or more). Adjusting time and concentration of transferrin load to cells, the influence of transferrin and treatment conditions on cell viability should be minded. Cells obtained as stated above very easily uptake transferrin in a relatively short time (in minutes; FIG. 8).

[0249] Nevertheless, the person skilled in the art is able to re-adjust the above conditions and optimize the protocol for the own purposes in the own laboratory.

Example 11—Ferritin/Haemoglobin/Transferrin-Macrophage Complex as Useful Delivery Tool to Cancer Cells

[0250] The macrophages from Example 1 prepared as described in Examples 8, 9 and 10, very easily transport ferritins, haemoglobins, transferrins to the cancer cells: mouse mammary cancer, colon cancer, canine mammary cancer, human breast, pancreatic, and bladder cancer (FIGS. 4, 10). Moreover, this transfer is much more specific to cancer cells than to non-cancer cells (FIG. 11). However, in case of cancer cells the ratio of both cell types is crucial. The more macrophages the better and faster the transport is. The most efficient transfer to the cancer cells was observed when ratio of macrophages to cancer cells was 1:1 or more.

[0251] This transfer occurred not only when the protein carriers are conjugated with fluorescent label (e.g. FITC or Alexa610), but also when they were conjugated/encapsulated with other compounds, e.g. anticancer drugs (FIG. 12 shows this transfer of ferritin encapsulated with fluorescent hypoxia activated prodrug—banoxantrone). This transfer of compounds conjugated with anticancer drugs made the effect inducing apoptosis in cancer cells (FIG. 6, 13).

Example 12—Ferritin/Haemoglobin/Transferrin-Monocyte Complex as Useful Delivery Tool to Cancer Cells

[0252] The monocytes from Example 2 prepared as described in Examples 8, 9 and 10, very easily transport ferritins, haemoglobins, transferrins to the cancer cells (FIG. 14). However, the ratio of both cell types is important. The more monocytes the better and faster the transport is. The most efficient transfer to the cancer cells was observed when ratio of monocytes to cancer cells was 1:1 or more.

Example 13—Ferritin/Haemoglobin/Transferrin-Granulocyte Complex as Useful Delivery Tool to Cancer Cells

[0253] The granulocytes from Example 3 prepared as described in Examples 8, 9 and 10, very easily transport ferritins, haemoglobins, transferrins to the cancer cells (FIG. 15). However, the ratio of both cell types is crucial. The more granulocytes the better and faster the transport is. The most efficient transfer to the cancer cells was observed when ratio of granulocytes to cancer cells was 1:1 or more.

Example 14—Ferritin/Haemoglobin/Transferrin-Lymphocyte Complex as Useful Delivery Tool to Cancer Cells

[0254] The lymphocytes from Example 4 prepared as described in Examples 8, 9 and 10, very easily transport ferritins, haemoglobins, transferrins to the cancer cells (FIG. 16). However, the ratio of both cell types is crucial. The more lymphocytes the better and faster the transport is. The most efficient transfer to the cancer cells was observed when ratio of lymphocytes to cancer cells was 1:1 or more.

Example 15—Cell Labeling with Radioisotope

[0255] In this invention cells were labeled with .sup.18F-FDG or .sup.89Zr-oxinate in order to become imaged on PET. Cells have been detached from the plate and incubated with .sup.18F-FDG or .sup.89Zr-oxinate solution in adequate concentration to ensure the most optimal .sup.18F-FDG or .sup.89Z-oxinate uptake by cells allowing their radio-detection at the site of their accumulation. In this practice of the invention cells were incubated at room temperature for at least 90 min. in .sup.89Zr-oxinate solution containing 3-9 MBq per 5 mln of cells. However, the ratio of radioisotope and cells influences significantly the reaction efficacy (FIG. 26). After labeling, cells are be centrifuged and supernatant is removed. This step should be repeated until no radioactivity is detected in the supernatant.

Example 16—Ferritin/Haemoglobin/Transferrin/Label-Leukocyte Complex as Useful Delivery Tool to Tumor, Arthritic Joints and Lymph Nodes

[0256] The macrophages from Example 1 prepared as described in Examples 9, 10, 11 and 11; monocytes from Example 2 prepared as described in Examples 9, 10, 11 and 12, granulocytes from Example 3 prepared as described in Examples 9, 10, 11 and 12, and lymphocytes from Example 4 prepared as described in Examples 9, 10, 11 and 12, highly efficiently migrate to the tumors (FIG. 22 and FIG. 23), arthritic joints (FIG. 24), in this particular example monocytic-macrophage cell line was used) and inflamed lymph nodes (FIG. 25), in this particular example monocyte/young macrophages activated using M-CSF and CCL-2 were used). Once they migrate to the tumors or other tissues they very easily transport ferritins, haemoglobins, transferrins and labels to the tumor in the enough amount to be detected using imaging systems (FIGS. 2, 3, 7, 17, and 18).

Example 17—Leukocyte-Protein Carrier Complex as Useful Targeted Pharmaceutically Active Substance Delivery System to Hypoxic Regions

[0257] Macrophages prepared as above are injected into the tail vein of animal with the tumour (appropriate number of macrophages should be adjusted to the tumour size, stage of development and presence of metastases). As it is shown on FIGS. 2, and 17 they specifically reach the tumour (after a few hrs) and also disperse in other organs of the whole animal (FIG. 18). Moreover, as it is shown on FIG. 19, in hypoxic model they are also able to migrate to the avascular and hypoxic sites and to transfer carrier proteins to cancer cells (FIGS. 3, and 20).

[0258] For the imaging purposes, 1-50 millions of macrophages were injected into the tail vein of mammary or colon cancer tumour-bearing animal. Before, macrophages were pre-labeled with Cell Tracker and loaded with ferritin-FITC (as shown in Example 8). Using two-photon of the tumour mass 8 hours after administration of macrophages the presence of macrophages carrying Ferritin-FITC was detected (FIG. 17). Their specific targeting of tumour but also their migration to other organs was shown using whole animal body imaging (IVIS) after macrophage pre-labeling using DIR cytoplasmic dye (FIG. 18).

[0259] The 1-10 millions of macrophages loaded with ferritin encapsulated cyclophosphamide, melphalan and ferritin encapsulated chlorambucil were injected i.v. into the tumour-bearing mice (300 000-500 000 of EMT6 cells injected into the skin flank). We made 3 injections of macrophages every third day (on the day 5, 8 and 11 after cancer cells injection or on the day 7, 10 and 13 after cancer cells injection) or five consecutive injections every day and we observed increased mouse survival (FIG. 5).

Example 18—Leukocyte-Protein Carrier Complex or Labeled Leukocyte as Useful Targeted Label Deliver Agent

[0260] The targeting of the targeted delivery system described in present invention can be followed by coupling the ferritin to a contrast agent. As it is presented on FIG. 21, after injection of 1-50 ml of macrophages loaded with ferritin coupled as described in Example 8 with a contrast agent (in this case: ferrihydrite, however the same results are obtained with isotope, e.g. .sup.123I) or labeled with isotope (in this case .sup.89Zr-oxide or 18F-FDG) (FIG. 21) they can be easily detected by MRI, PET or SPECT. In this example (FIG. 7), mammary-tumour bearing mice were imaged using MRI at 3, 22 and 24 hours after i.v. injection of macrophages loaded with ferritin Fh. The mouse was treated (at time point 0 h) with macrophages. Then increased diameter of blood vessels (arrow) filled with injected macrophages (giving significant T2-signal reduction) has been observed and afterword macrophages spread to the tissue (spot-like pattern; arrows). These changes (in the same time points) were observed in all examined mice.

[0261] Macrophages were also labeled with .sup.89Zr-oxide or .sup.18F-FDG (5-50 mln) and their radioactivity was confirmed to be imaged using PET after i.v. administration to the tumour-bearing mice. These mice were inoculated with 4T1 metastatic cell line 3 weeks before the experiment and metastases in the lungs, liver and spleen were histopatologically confirmed. At FIG. 21 it is seen that macrophages migrated to the regions with metastatic tumours allowing their visualization at PET.

[0262] While the foregoing written description of the invention enables one of ordinary skill to make and use what is considered presently to be the best mode thereof, those of ordinary skill will understand and appreciate the existence of variations, combinations, and equivalents of the specific embodiment, method, and examples herein. The invention should therefore not be limited by the above described embodiment, method, and examples, but by all embodiments and methods within the scope and spirit of the invention.